HEATHER GILCREASE: Open Payments
NPI 1184154817 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 43 payments from 18 companies in 2025. Trend: 2023 $213 · 2024 $402 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $157 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $99 |
| Lilly USA, LLC | 4 | $81 |
| ABBVIE INC. | 3 | $77 |
| Corium, LLC | 3 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| TOLMAR, INC. | 3 | $45 |
| Exact Sciences Corporation | 2 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
Products named: XIFAXAN, Azstarys, VRAYLAR, Wegovy, AIRSUPRA, Rybelsus, JATENZO, JARDIANCE.
Industry payments across TX — which companies pay providers there.
